



# **A pharmaceutical study on photodynamic therapy of skin diseases**

*A Thesis submitted*

*By*

*Mai Shaaban Abdel Aziz Tolba*

*Bachelor of Pharmaceutical Science, 2009, Ain Shams University*

*Teaching assistant, Department of Pharmaceutics, Faculty of Pharmacy, Ain Shams  
University*

*For the partial fulfillment of the requirements for the Master Degree of Pharmaceutical  
Sciences (Drug Technology)*

*Under the supervision of*

*Prof. Dr. Omaila Ahmed Sammour*

*Professor of Pharmaceutics and*

*Industrial Pharmacy*

*Faculty of Pharmacy, Ain Shams*

*University*

*Prof. Dr. Maha Fadel Mohamed*

*Professor of Pharmaceutics*

*National institute of laser sciences*

*Cairo University*

*Dr. Maha Nasr Sayd*

*Associate Professor of Pharmaceutics and Industrial pharmacy*

*Faculty of Pharmacy*

*Ain Shams University*

**Ain Shams University**

**Faculty of Pharmacy**

**Department of Pharmaceutics and Industrial pharmacy**

**2018**

## *Acknowledgment*

First and foremost thanks to **Allah** by the grace of whom this work was achieved.

To my dear supervisors, these written words are a small token of appreciation for all of the hard work that you did to keep things in perspective.

I would like to express my deepest appreciation to ***Prof. Dr. Omaina Sammour***, Professor of Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, for her instructive supervision, precious advice and supportive encouragement throughout the development of this work.

I am also grateful to ***Prof. Dr. Maha Fadel***, Professor of Pharmaceutics, National institute of laser sciences, Cairo University, for her great help, support and guidance, especially in the photostability study.

I would also like to express my sincere gratitude and thanks to my supervisor ***Dr. Maha Nasr***, Associate Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain shams University, for her great effort that she exerted throughout my thesis. Her guidance helped me a lot in all the time of work and writing of this thesis. She provided me with great knowledge, valuable suggestions and solutions to every trouble I fell into

---

during this work. This work wouldn't have been possible without her supervision and her keen interest. I am gratefully indebted to her.

I would also like to thank ***Prof. Dr. Abeer Ateya*** professor of Dermatology, Faculty of Medicine, Cairo University, for her kind help in the clinical study part in this thesis.

I am deeply thankful to ***Gattefosse*** and ***Cargill*** Pharmaceutical Companies for supplying some of the pharmaceutical ingredients used in this work.

A very special gratitude goes out to all my ***colleagues*** in the department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain shams University, for helping and encouraging me throughout the whole thesis.

Finally, I must express my very profound gratitude to my mother, my father, my brothers, my sister and my husband for providing me with continuous encouragement and support throughout the years of work in this thesis.

---

## List of Contents

<b>Item</b>	<b>Page</b>
<b>List of abbreviations</b>	<b>I</b>
<b>List of tables</b>	<b>V</b>
<b>List of figures</b>	<b>VIII</b>
<b>Abstract</b>	<b>XIV</b>
<b>Introduction</b>	<b>1</b>
<b>Scope of work</b>	<b>35</b>
<b>Chapter I: Preparation and characterization of bergamot oil NLCs</b>	
<b>Introduction</b>	<b>36</b>
<b>Experimental</b>	<b>38</b>
<b>Materials</b>	<b>38</b>
<b>Equipment</b>	<b>39</b>
<b>Methodology</b>	<b>40</b>
<b>I- Spectrophotometric assay of bergamot oil</b>	<b>40</b>
1. UV scanning of bergamot oil in phosphate buffer solution containing 5 % SLS and in tetrahydrofuran	40
2. Construction of calibration curve of bergamot oil in phosphate buffer solution containing 5 % SLS and in tetrahydrofuran	40
<b>II-Preparation of bergamot oil NLCs</b>	<b>41</b>
a. High shear homogenization method	41
b. Solvent diffusion method	43
<b>III- Characterization of the prepared BO NLCs</b>	<b>44</b>

---

---

1. Particle size and zeta potential measurement	44
2. Physical stability study	44
3. <i>In vitro</i> release study	44
4. Differential scanning calorimetry	45
5. Viscosity measurements	46
6. <i>In vitro</i> photostability study	46
7. Transmission electron microscopy	47
<b>IV- Statistical analysis</b>	47
<b>Results and Discussion</b>	48
<b>I- Spectrophotometric assay of bergamot oil</b>	48
1. UV scanning of BO in phosphate buffer solution containing 5 % SLS and in tetrahydrofuran	48
2. Construction of calibration curve of BO in phosphate buffer solution containing 5 % SLS and in tetrahydrofuran	48
<b>II- Preparation of BO NLCs</b>	53
<b>III- Characterization of the prepared BO NLCs</b>	55
1. Particle size and zeta potential measurements of BO NLCs	55
1-1. Effect of solid lipid type on the particle size of BO NLCs	57
1-2. D-Optimal custom design model for the effect of method of preparation, emulsifier and coemulsifier types on the particle size of Precirol-based NLCs	58
1-2.1. Effect of method of preparation on the particle size of BO NLCs	59

---

---

1-2.2. Effect of emulsifier type on the particle size of BO NLCs	60
1-2.3. Effect of coemulsifier presence on the particle size of BO NLCs	65
2. Zeta potential measurements of the prepared BO NLCs	69
2-1. Effect of solid lipid type on the zeta potential of BO NLCs	69
2-2. Effect of emulsifier type on the zeta potential of BO NLCs	70
2-3. Effect of coemulsifier presence on the zeta potential of BO NLCs	71
3. Physical stability study	73
4. <i>In vitro</i> release of BO from NLCs	75
5. Differential scanning calorimetry	78
6. Determination of the viscosity of BO NLCs	81
7. <i>In vitro</i> photostability study	82
8. Transmission electron microscopy examination	86
<b>Conclusions</b>	88
<b>Chapter II: Preparation and characterization of BO loaded spanlastics</b>	
<b>Introduction</b>	91
<b>Experimental</b>	93
<b>Materials</b>	93
<b>Equipment</b>	93

<b>Methodology</b>	94
<b>I- Preparation of BO-loaded spanlastics</b>	94
<b>II-Characterization of the prepared BO-loaded spanlastics</b>	95
1. Particle size and zeta potential measurement	95
2. Physical stability study	95
3. <i>In vitro</i> release study	96
4. Differential scanning calorimetry	96
5. Viscosity measurements	96
6. Elasticity measurements	97
7. <i>In vitro</i> photostability study	97
8. Transmission Electron Microscopy	98
<b>III- Statistical analysis</b>	98
<b>Results and Discussion</b>	99
<b>I- Preparation of BO-loaded spanlastics</b>	99
<b>II-Characterization of the prepared BO-loaded spanlastics</b>	100
1. Factorial design experiment	100
1-1. Effect of formulation variables on the particle size of spanlastics	100
1-2. Zeta potential measurements	105
2. Physical stability study	109
3. <i>In vitro</i> release of BO from spanlastics	112
4. Differential scanning calorimetry (DSC)	115

5. Determination of the viscosity of BO-loaded spanlastics dispersions	117
6. Elasticity measurements	118
7. <i>In vitro</i> photostability study	119
8. Transmission electron microscopy examination	122
<b>Conclusions</b>	125
<b>Chapter III: <i>In vivo</i> and clinical evaluation of the selected Bergamot oil loaded NLCs and spanlastics for photodynamic treatment of vitiligo</b>	
<b>Introduction</b>	127
<b>Experimental</b>	130
<b>Materials</b>	130
<b>Equipment</b>	130
<b>Methodology</b>	131
<b>I- <i>In vivo</i> study</b>	131
1- Experimental animals	131
2- Histopathological examination following animal skin photosensitization	131
<b>II- Clinical proof of efficacy of the selected formulae in the treatment of vitiligo</b>	133
1- Design of the clinical study	133
2- Clinical response	133
<b>III- Statistical analysis</b>	135
<b>Results and Discussion</b>	136
<b>I- Histopathological alterations following rat skin photosensitization</b>	136
<b>II- Clinical proof of efficacy of selected NLCs and</b>	142



<b>spanlastics formulations in PDT of vitiligo</b>	
<b>Conclusions</b>	156
<b>Recommendations and Future perspective</b>	157
<b>Summary</b>	158
<b>References</b>	167
<b>Appendix</b>	196
<b>Arabic Summary</b>	١

---

**List of Abbreviations**

Symbol	Abbreviation
$\mu$ W	Microwatt
5-GOP	5-geranoxypsoralen
5-MOP	5-methoxypsoralen
8-MOP	8-methoxypsoralen
AKs	Actinic keratoses
ANOVA	Analysis of variance
aPDT	Antimicrobial photodynamic therapy
BO	Bergamot oil
BO NLCs	Bergamot oil-nanostructured lipid carriers
Cor	Correlation
cP	Centipoise
DSC	Differential scanning calorimetry
GRAS	Generally regarded as safe
HLB	Hydrophilic lipophilic balance
Hp	Hematoporphyrin
HPHs	High pressure homogenizers
hr	Hour
HSH	High shear homogenization
<i>I</i>	Irradiance

Symbol	Abbreviation
J	Joule
$\lambda_{\max}$	The wavelength of maximum absorbance
LNPs	Lipid nanoparticles
MBEH	Monobenzyl ether of hydroquinone
MCT	Medium chain triglyceride
MEL	Monochromatic excimer light
min	Minute
ml	Milliliter
MPa	Megapascal
mV	Millivolt
Mwt	Molecular weight
nBCC	Nodular basal cell carcinoma
NB-UVB	Narrowband-ultraviolet B
NLCs	Nanostructured lipid carriers
nm	Nanometer
PB	Phosphate buffer
PDI	Polydispersity index
PDT	Photodynamic therapy
PEG	Polyethylene glycol
P-NBUVB	Psoralen + Narrowband ultraviolet B
PQPs	Perylenequinone pigments

Symbol	Abbreviation
PS	Plurol Stearique <sup>®</sup> WL 1009
PSs	Photosensitizers
PUVA	Psoralen + ultraviolet A
PUVB	Psoralen + ultraviolet B
R <sup>2</sup>	Coefficient of determination
RI	Recrystallization index
rpm	Revolution per minute
S.D.	Standard deviation
sBCC	Superficial basal cell carcinoma
SC	Stratum corneum
SCCIS	Squamous cell carcinoma <i>in situ</i>
SD	Solvent diffusion
sec	Second
SG	Stratum granulosum
SLNs	Solid lipid nanoparticles
SLS	Sodium lauryl sulphate
SP	Stratum spinosum
$t_{1/2}$	Half-life time
T80	Tween 80
Tc	Crystallization temperature
TEM	Transmission electron microscope

Symbol	Abbreviation
THF	Tetrahydrofuran
TMP	4-, 5-, 8-trimethyl psoralen
UV	Ultraviolet
UVA	Ultraviolet A
UVB	Ultraviolet B
ZP	Zeta potential

### List of Tables

Table No.	Table Name	Page
<b>Table (1)</b>	Composition of BO NLCs prepared using HSH method	42
<b>Table (2)</b>	Composition of BO NLCs prepared using SD method	43
<b>Table (3)</b>	Calibration data for the spectrophotometric determination of BO in PB solution (PH 7.4) with 5% SLS at 292 nm	50
<b>Table (4)</b>	Calibration data for the spectrophotometric determination of BO in THF at 292 nm	51
<b>Table (5)</b>	Particle size, polydispersity index and zeta potential of BO NLCs prepared using HSH method	56
<b>Table (6)</b>	Particle size, polydispersity index and zeta potential of BO NLCs prepared using SD method	57
<b>Table (7)</b>	Effect of three months storage at 2-8°C on the particle size, PDI and zeta potential of T80 stabilized NLCs prepared by HSH and SD methods	73
<b>Table (8)</b>	<i>In vitro</i> release data of the selected BO NLCs	76
<b>Table (9)</b>	Melting peaks, enthalpies and crystallinity indices of Precirol ATO 5, Compritol 888 ATO, D6 and H12	81
<b>Table (10)</b>	The degradation half-life, $t_{1/2}$ , degradation rate constant, $K$ , and $R^2$ values of BO in THF solution and BO incorporated in D6 and H12	86
<b>Table (11)</b>	Factors and levels used in the factorial design for the preparation of BO-loaded spanlastics dispersions	94

Table No.	Table Name	Page
<b>Table (12)</b>	Composition of BO-loaded spanlastics dispersions for the factorial design	95
<b>Table (13)</b>	Vesicle size, polydispersity index and zeta potential of BO-loaded spanlastics	101
<b>Table (14)</b>	ANOVA for particle size response of BO-loaded spanlastics according to the factorial design	103
<b>Table (15)</b>	ANOVA for ZP response of BO-loaded spanlastics according to the factorial design	107
<b>Table (16)</b>	Effect of one month storage at 2-8°C on the vesicle size, PDI and zeta potential of BO-loaded spanlastics	110
<b>Table (17)</b>	<i>In vitro</i> release data of the selected BO-loaded spanlastics	113
<b>Table (18)</b>	The degradation half-life, $t_{1/2}$ , degradation rate constant, $K$ , and $R^2$ values of BO in THF solution and BO loaded in S6	122
<b>Table (19)</b>	Animal groups for the topical photodynamic therapy	132
<b>Table (20)</b>	Demographic data of group A patients receiving NB-UVB light	142
<b>Table (21)</b>	Demographic data of group B patients receiving S6 formulation + NB-UVB light	143
<b>Table (22)</b>	Demographic data of group C patients receiving D6 formulation + NB-UVB light	144
<b>Table (23)</b>	Clinical response of group A patients receiving NB-UVB light	145